The EVARREST® Fibrin Sealant Patch Liver Study
A Phase III Randomized, Controlled, Superiority Study Evaluating EVARREST® Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery
Sponsor: Ethicon, Inc.
A PHASE3 clinical study on Hemorrhage, this trial is completed. The trial is conducted by Ethicon, Inc. and has accumulated 11 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Nov 2020 [monthly]
Completed PHASE3
-
May 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Aug 2017 — May 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ethicon, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .